Understand the source comparison
Epithalon Metabolism Research: Compound Comparison
Primary metabolic pathway Hepatic CYP3A4/CYP2D6 → renal elimination Hepatic peptidase cleavage → biliary excretion Hepatic first-pass → renal clearance Epithalon's cytochrome involvement makes it uniquely susceptible to drug-drug interactions. Critical conside
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary metabolic pathway
- Hepatic CYP3A4/CYP2D6 → renal elimination
- Hepatic peptidase cleavage → biliary excretion
- Hepatic first-pass → renal clearance
- Epithalon's cytochrome involvement makes it uniquely susceptible to drug-drug interactions. Critical consideration for polypharmacy research protocols
- Plasma half-life (subcutaneous)
- 4.8 days
- 2.1 days
- 3.2 days
- Epithalon's extended half-life allows less frequent dosing but increases washout time between experimental cycles
- Peak tissue concentration
- Pineal gland (8–12× plasma)
- Thymus (6–8× plasma)
- Cerebral cortex (5–7× plasma)
- Tissue-specific accumulation patterns determine optimal compound selection based on target organ system
- Bioavailability (subcutaneous)
- 40–60%
- 30–45%
- 35–50%
- Epithalon's higher bioavailability reflects greater resistance to extrahepatic peptidases. Purity matters significantly for achieving published values
- Duration of biological effect
- 10–14 days post-dose
- 5–7 days post-dose
- 7–10 days post-dose
- Effect persistence exceeds plasma detection for all three compounds. Designing washout periods based on half-life alone underestimates carryover effects by 40–60%